Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Apr 12

PMID 33841331

Citations 10

Authors

Xiaoyan Ren

Zhihui Zhang

Zhaoli Yan

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein (a) [Lp (a)] has been well recognized as a risk factor of cardiovascular disease. However, the association between serum Lp (a) and diabetic nephropathy in patients with type 2 diabetes mellitus (T2DM) remains unknown. We performed a meta-analysis to comprehensively evaluate the above association.

Methods: Observational studies aiming to evaluate the independent association between serum Lp (a) and diabetic nephropathy in T2DM patients were identified by systematic search of PubMed and Embase databases. A random-effect model which incorporated the potential intra-study heterogeneity was used for the meta-analysis.

Results: Eleven observational studies with 9304 T2DM patients were included. Results showed that compared to those with the lowest Lp (a), patients with the highest Lp (a) level had higher odds of diabetic nephropathy (adjusted odds ratio [OR]: 1.63, 95% confidence interval [CI]: 1.25-2.14, I = 54%, P < 0.001). Meta-analysis of studies in which Lp (a) was presented as continuous variables showed consistent result (adjusted OR: 1.13 for 1 mg/dl increment of Lp (a), 95% CI: 1.03-1.24, I2 = 36%, P = 0.008). Subgroup analyses showed that study characteristics such as definitions of diabetic nephropathy and study design did not significantly affect the association (P for subgroup difference all > 0.05).

Conclusions: Higher serum Lp (a) in patients with T2DM is independently associated with higher odds of diabetic nephropathy. Large scale prospective cohort studies are needed to validate this finding. Moreover, the potential influence of Lp (a) lowering on renal function in T2DM patients may be further investigated.

Citing Articles

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and diabetic kidney disease in patients with diabetes in the United States: a cross-sectional study.

Pan J, Li C, Zhang J, Sun Z, Yu X, Wan Q Lipids Health Dis. 2024; 23(1):317.

PMID: 39334123 PMC: 11437633. DOI: 10.1186/s12944-024-02308-5.

Relationship Between Lipoprotein(a), Renal Function Indicators, and Chronic Kidney Disease: Evidence From a Large Prospective Cohort Study.

Liu Y, Wang R, Li S, Zhang C, Lip G, Thabane L JMIR Public Health Surveill. 2024; 10:e50415.

PMID: 38294877 PMC: 10867749. DOI: 10.2196/50415.

Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes.

Li M, Wang Y, Yao Q, Liang Q, Zhang Y, Wang X Front Endocrinol (Lausanne). 2024; 14:1337469.

PMID: 38288472 PMC: 10822945. DOI: 10.3389/fendo.2023.1337469.

Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review.

Martinez-Hernandez S, Munoz-Ortega M, Avila-Blanco M, Medina-Pizano M, Ventura-Juarez J Biomedicines. 2023; 11(10).

PMID: 37893201 PMC: 10604533. DOI: 10.3390/biomedicines11102828.

Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods.

Fogacci F, Di Micoli V, Avagimyan A, Giovannini M, Imbalzano E, Cicero A Int J Mol Sci. 2023; 24(18).

PMID: 37762189 PMC: 10531419. DOI: 10.3390/ijms241813886.

References

Sattar N, Preiss D, Robinson J, Djedjos C, Elliott M, Somaratne R . Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 2016; 4(5):403-10. DOI: 10.1016/S2213-8587(16)00003-6. View

Hermans M, Ahn S, Rousseau M . The mixed benefit of low lipoprotein(a) in type 2 diabetes. Lipids Health Dis. 2017; 16(1):171. PMC: 5596924. DOI: 10.1186/s12944-017-0564-9. View

Heinrich N, von Scholten B, Reinhard H, Persson F, Ahluwalia T, Hansen T . Lipoprotein(a)and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. J Diabetes Complications. 2020; 34(7):107593. DOI: 10.1016/j.jdiacomp.2020.107593. View

Lin J, Reilly M, Terembula K, Wilson F . Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One. 2014; 9(12):e114397. PMC: 4260843. DOI: 10.1371/journal.pone.0114397. View

Ghaedi E, Kord-Varkaneh H, Mohammadi H, Askarpour M, Miraghajani M . Phytosterol Supplementation Could Improve Atherogenic and Anti-Atherogenic Apolipoproteins: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Coll Nutr. 2019; 39(1):82-92. DOI: 10.1080/07315724.2019.1605313. View

Lin J, Hu F, Mantzoros C, Curhan G . Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia. 2009; 53(2):263-7. PMC: 2809803. DOI: 10.1007/s00125-009-1597-z. View

Mondorf U, Piiper A, Herrero M, Olbrich H, Bender M, Gross W . Lipoprotein(a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins. Kidney Int. 1999; 55(4):1359-66. DOI: 10.1046/j.1523-1755.1999.00367.x. View

Charlton A, Garzarella J, Jandeleit-Dahm K, Jha J . Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. Biology (Basel). 2021; 10(1). PMC: 7830433. DOI: 10.3390/biology10010018. View

Zhang X, Kong J, Yun K . Prevalence of Diabetic Nephropathy among Patients with Type 2 Diabetes Mellitus in China: A Meta-Analysis of Observational Studies. J Diabetes Res. 2020; 2020:2315607. PMC: 7023800. DOI: 10.1155/2020/2315607. View

10.

Hopewell J, Haynes R, Baigent C . The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018; 59(4):577-585. PMC: 5880503. DOI: 10.1194/jlr.R083626. View

11.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

12.

Tseng C . Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. Clin Biochem. 2009; 42(10-11):1019-24. DOI: 10.1016/j.clinbiochem.2009.03.013. View

13.

Moosaie F, Firouzabadi F, Abouhamzeh K, Esteghamati S, Meysamie A, Rabizadeh S . Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study. Nutr Metab Cardiovasc Dis. 2020; 30(10):1723-1731. DOI: 10.1016/j.numecd.2020.05.011. View

14.

Sulaiman M . Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 2019; 11:7. PMC: 6343294. DOI: 10.1186/s13098-019-0403-4. View

15.

Riis Hansen P, Kharazmi A, Jauhiainen M, Ehnholm C . Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994; 24(7):497-9. DOI: 10.1111/j.1365-2362.1994.tb02381.x. View

16.

Awad K, Mikhailidis D, Katsiki N, Muntner P, Banach M . Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs. 2018; 78(4):453-462. DOI: 10.1007/s40265-018-0870-1. View

17.

Jha J, Ho F, Dan C, Jandeleit-Dahm K . A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin Sci (Lond). 2018; 132(16):1811-1836. DOI: 10.1042/CS20171459. View

18.

Patsopoulos N, Evangelou E, Ioannidis J . Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008; 37(5):1148-57. PMC: 6281381. DOI: 10.1093/ije/dyn065. View

19.

Orso E, Schmitz G . Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl. 2017; 12(Suppl 1):31-37. PMC: 5352764. DOI: 10.1007/s11789-017-0084-1. View

20.

Sahebkar A, Simental-Mendia L, Watts G, Serban M, Banach M . Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017; 15(1):22. PMC: 5290642. DOI: 10.1186/s12916-017-0787-7. View